List of 24 Acquisitions by Bristol-Myers Squibb (Jul 2026) - Tracxn

JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn.

Internal Server Error

Most viewed in 2019

Bristol-Myers Squibb has made a total of 24 acquisitions. It completed 24 acquisitions across 12 sectors, including Oncology, Immunotherapy, and Diversified Pharmaceuticals. These activities span 4 countries: United States, France, and Sweden. Peak acquisition years were 2023 with 3 acquisitions, and 2025 and 2020 with 2 acquisitions each. Between 2020 and 2025, it maintained an average of 1.2 acquisitions per year, with 0 acquisitions completed in the current calendar year. In October 2025, it acquired Orbital Therapeutics, a Yellow Springs-based distributor of RNA medicines founded in 2022.

Here's the year on year acquisition history of Bristol-Myers Squibb:

Number of Total Acquisitions

Year	# Acquisitions
2025	2
2023	3
2022	1
2020	2
2019	1
2017	1
2016	2
2015	2
2014	2
2012	2
2011	1
2010	1
2009	1
2008	1
2007	1
1994	1

View all Acquisitions by Bristol-Myers Squibb

Recent acquisitions by Bristol-Myers Squibb

Bristol-Myers Squibb's most recent acquisition - Orbital Therapeutics is a Distributor of RNA medicines, founded in 2022 and located in Yellow Springs. Bristol-Myers Squibb acquired it in October 2025 for a price of $*****.

Here is the list of all acquisitions by Bristol-Myers Squibb sorted by the latest acquisition date:

Acquired on	Acquired Company	Acquisition Price	Facilitators	Stake Acquired	Acquisition Multiple
Oct 10, 2025	Orbital Therapeutics	hibq	aosf	22	100
Mar 11, 2025	2seventy bio	snxy	klev	33	989
Dec 26, 2023	RayzeBio	wtsn	rnaq	52	981
Dec 22, 2023	Karuna Therapeutics	hynr	zjof	39	175
Oct 09, 2023	Mirati Therapeutics	eggy	cvwu	86	984

View the full list of acquisitions

Sign Up for Free

Media has covered Bristol-Myers Squibb for a total of 219 events in the last 1 year, 36 of them have been about acquisition activity.

•

Bristol Myers Squibb Deploys NVIDIA DGX Vera Rubin Systems for AI-Powered R&DContract Pharma•Jul 20, 2026•Bristol-Myers Squibb, Nvidia, SSI

•

Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, CanadaCNW•Jul 15, 2026•Bristol-Myers Squibb, Septa Pharmaceuticals

•

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the DiseaseBusiness Wire•Jun 08, 2026•Bristol-Myers Squibb

•

Korean BMS Pharmaceutical to Discover Domestic Innovative Technologies with Seoul City for 5 Consecutive YearsKorea Newswire•Jun 05, 2026•Seoulbiohub, Bristol-Myers Squibb

•

Pfizer and Innovent Biologics Partner to Advance Oncology MedicineWorld Business Outlook•May 29, 2026•Innovent Bio, Pfizer, Bristol-Myers Squibb, Chai Discovery

•

Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global OperationsBusiness Wire•May 20, 2026•Bristol-Myers Squibb, Anthropic

•

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and NeuroscienceBusiness Wire•May 14, 2026•Bristol-Myers Squibb, Tempus

•

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative MedicinesPR Newswire•May 12, 2026•Hengrui, Bristol-Myers Squibb, Tempus, Lonza

•

Bristol Myers Squibb-Pfizer Alliance to sell Eliquis on Mark Cuban’s Cost Plus DrugsBee Star•Apr 24, 2026•Cost Plus Drug, Bristol-Myers Squibb, Pfizer, Mark Cuban Cost Plus Drug Company

•

Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP DeletionBusiness Wire•Apr 21, 2026•Bristol-Myers Squibb, Foundation Medicine

View More Bristol-Myers Squibb Recent News

View all Acquisitions by Bristol-Myers Squibb

Tracxn powers 1,000+ customers across 30+ countries